ArticleHuman vaccines & immunotherapeutics2014

Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study.

Giovanna Orlando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.